On July 29^th, 2022, Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort® MedBot®”) was named one of the 50 Smartest Companies in 2021 by MIT Technology Review (“MIT TR50”). Mr. Liuyu, the Executive Vice President and Chief Business Officer of MicroPort® MedBot®, was invited to the EmTech China Global Emerging Technology Summit and 50 Smart Companies Launch Ceremony. As the first surgical robot company selected into TR50 in China, MicroPort® MedBot® provides comprehensive intelligent surgical solutions to prolong and reshape the lives of patients. It also leads the intelligent transformation in the medical field with excellent robotic technologies and innovation capacity.

MicroPort® MedBot® Named “One of the 50 Smartest Companies”

As a long-standing influential media focusing on emerging technologies in the world, MIT Technology Review picks the 50 companies in the world that are smartest about how they combine innovative technology with an effective business model every year since 2010. The named companies feature outstanding strength in emerging technologies. According to MIT Technology Review, emerging technologies mean science and technologies that have the potential to achieve commercialization within 3 to 5 years. The influence of emerging technologies development will transcend geographic boarders, and brings about different changes depending on the condition and environment of different regions, markets and industries, which will then quickly spread to the rest of the world. 

“The best way to predict the future is to create it.” MicroPort ^® MedBot^® starts to develop intelligent surgical robotic systems and solutions from 2014. Now, the current business covers five “Gold Races” of surgery robots, including laparoscopic, orthopaedic, trans-natural orifice and percutaneous surgical solutions. Through continuous exploration and research, MicroPort® MedBot® achieved significant breakthroughs in technologies and clinical application, and realized diversified development, global presence and group operation. It is now leading and accelerating the innovation and development of domestic robotic technologies, extending the application of surgical robots, empowering and improving the diagnostics and treatment of primary medical and health care institution around the world.

Recent years, as the only surgical robot company covering the five “Gold Races”, MicroPort® MedBot® has created many records as the first or the only company in the industry. In January 2022, Toumai^® laparoscopic surgical robot (MedBot^® Toumai^®), independently developed by the Group, obtained the approval of NMPA for marketing. This will play a significant role for our country to boost the development of surgical robot industry, and rapidly improve the clinical performance of robotic surgery in China.    

Advantages

“Toumai^® laparoscopic surgical robot is the first four-arm laparoscopic robot approved for marketing developed by a Chinese company. Featuring the only force displaying function in the world, it has solved the technology bottleneck of operation force displaying that has bothered the laparoscopic surgical robot field for decades. So far, three flagship products, namely, DFVision^® 3D Electronic Laparoscope, Toumai^® Laparoscopic Surgical Robot and Honghu Orthopedic Surgery Robot have all been approved for marketing.”

Recently, MedBot^®Toumai^® has completed the world's longest-range 5G tele-robotic surgery, proving the breakthrough and leading position of our country in ultra-long-range 5G robotic surgeries.

Keyword: 5000 km

“Toumai^® minimizes the delay of images and control through breakthroughs in core technologies such as 5G remote control, simultaneous transmission of high capacity images, and enables real-time monitoring and early warning of network communication quality to ensure safe and smooth completion of the 5G robotic surgery over a distance of 5,000 km. In June 2022, three ultra-long-range 5G robotic surgeries in urology through 5G connection between Xinjiang Kezhou People's Hospital and Jiangsu Province People's Hospital were completed. These three surgeries were nearly 5,000 km apart, making them the longest 5G remote robotic surgeries in the world to date.”

The plentiful achievements made by MicroPort® MedBot® are based on a global innovation platform for comprehensive surgical robot solutions established through the integration of fundamental technologies, the mode of production-education-research-treatment, and diversified operation, thus leading the development trend of global surgical robot industry.      

Whole Chain of Underlying Technology Innovation

Over years of R&D, innovation and accumulation, MicroPort® MedBot® has developed into a group company that employs nearly one thousand of engineers, technicians and professional talents, and boosts full chain fundamental technologies in the field of surgical robots. It has established global R&D center in Singapore and the USA to attract top talents and establish international innovation platform with deep integration of technology R&D and industry consolidation.

Innovation through Deep Integration of Production, Education, Research and Treatment

Clinical demands are the source of inspiration for technology innovation. MicroPort® MedBot® fully leverage the advantage of integration of treatment and industry to rapidly respond to market demands. Furthermore, it has vigorously implemented multi-center clinical trials led by domestic clinicians, promoting industry upgrade, product iteration, and conversion of fundamental research into achievements. The Group also established Shanghai minimally invasive surgery robot engineering and technology research center to create an open service platform covering R&D, qualification, clinical and commercialization support through coordination of industry, education, and development as well as clinical cooperation.

MicroPort® MedBot® adopts the strategy of group operation, and covers the R&D and manufacturing of surgical robots of different application fields. It provides patients with comprehensive intelligent surgical robot solutions throughout the whole cycle of before, during and after the surgery, and products meeting the diagnostics and treatment demands of patients from multiple departments.      Meanwhile, the Group is committed to building an innovative platform for medical robot total solution with global presence, and promoting strategic cooperation around the world.

Mr. Liuyu, the Executive Vice President and Chief Business Officer of MicroPort® MedBot®, expressed: “In 2021, the Group has made multiple breakthroughs in the frontier research and industry integration of robot bodies, intelligent control, sensing and information, where we have achieved the most important technology innovations. These breakthroughs have helped multiple innovative surgical robots enter or complete the stage of clinical study for registration.” Boosting the whole chain of underlying technologies and an all-round technology innovation platform for surgical robots, MicroPort® MedBot® has a strong capacity for product range expansion and innovation, all of which make it the only surgical robot company in the world with a product portfolio covering the five major and fast growing surgical specialties. MicroPort® MedBot® represents the future of intelligent medical industry. We will continue to promote innovation, accelerate the progress of R&D and commercialization, lead the maturity and development of robotic surgery, and shape the era of super-intelligent surgery, realizing the original aspiration of “Make Surgery Easier, Safer and Less Invasive”.

Founded in 1899, MIT Technology Review is the oldest technology magazine in the world with significant influence. Since 2011, MIT Technology Review has started to select 50 Smartest Companies. Over 9 years of development, it has become one of the most authoritative technology list in the world, and is reputed as the bellwether of global technology development.